19 October 2020 - Swissmedic said the United States pharmaceutical company Pfizer submitted an application for the authorisation of a vaccine which is based on the mRNA technology last week.

The agency added it is fast-tracking all applications connected with the Covid-19 pandemic, assigning extra staff to this task so that content checks and, in particular, user safety are not compromised.

The criteria for reviewing safety, efficacy and quality remain unchanged, according to Claus Bolte, head of Swissmedic’s authorisation division.

Read Swissmedic press release